Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULFAIR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULFAIR 15.
AVC vs SULFAIR-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
15 mg orally every 6 hours, not to exceed 60 mg/day.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)